You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it. In addition as per local health authority Regulations, some of our products are not approved for sales, marketing or distribution in all countries.
NO
YES

  1. CORPORATE - 18-01-2016

    A brand new location for KEDPlasma donors in the very center of Fürth

    Plasma collected is turned into life-saving therapies to serve patients in Germany and worldwide

    read more 

  2. CORPORATE - 08-01-2016

    KEDPlasma acquires two plasma centers from ImmunoTek LLC in the US

    The acquisition is part of a five-year growth plan of supplying highest-quality plasma to Kedrion Biopharma

    read more 

  3. CORPORATE - 07-01-2016

    Human rabies Ig meets primary endpoint in U.S. pivotal phase 2/3 clinical trial

    Strategic agreement between Kedrion and Kamada for its clinical development and marketing

    read more 

  4. CORPORATE - 12-10-2015

    Kedrion supports Fondazione Paracelso's activities in Afghanistan

    Kedrion confirms its commitment to broaden access to hemophilia treatments in developing Countries

    read more 

Pages

For more information please contact: pressoffice@kedrion.com